In the combination antiretroviral therapy (cART) era, the incidence of Hodgkin lymphoma (HL) has not decreased, with some studies reporting it may have increased. The incidence of HL is approximately 10-fold higher in HIV-positive subjects. In this population, HL has a more aggressive behavior, including more advanced stage and extranodal involvement at diagnosis. Different chemotherapy regimens have been used, including ABVD, Stanford V and BEACOPP. The concomitant administration of chemotherapy and cART has been shown to have a favorable impact on clinical outcomes and overall survival. As a consequence, current recommendations suggest to treat HL in HIV-positive subjects similarly to uninfected ones and to give concomitantly cART and adequate supportive therapy.
Here, we describe a case of nodular sclerosis HL in a patient with HIV infection, who achieved remission with ABVD chemotherapy, but unfortunately relapsed and died two years after the initial diagnosis.
To cite this article
Relapsed nodular sclerosis Hodgkin lymphoma in a patient with HIV infection
WCRJ 2014; 1 (4): e389
Published online: 20 Dec 2014